Compare Organon & Co. Common Stock (OGN) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Materials Select Sector SPDR Fund — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Materials Select Sector SPDR Fund trades at $49.67 (market cap $7.85B). The key difference: Materials Select Sector SPDR Fund is far larger — about 2.2× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Materials Select Sector SPDR Fund for 71 Days on average.
| OGN | XLB | |
|---|---|---|
Market Cap | $3.62B | $7.85B |
Volume | 2,892,999 | 7,897,808 |
Sector | Health | — |
52-Week High | $13.81 | $53.67 |
52-Week Low | $5.70 | $42.23 |
Typical Hold Time | 0 Days | 71 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
XLB trades at $49.72 with a modest 0.57% daily gain, though technical indicators signal bearish momentum with moving averages and ADX pointing lower. The materials ETF faces headwinds from sector concentration risks, with chemicals comprising 49% of assets. Recent analysis suggests much of the cyclical recovery appears priced in, limiting near-term upside potential despite infrastructure and manufacturing tailwinds.
Outlook remains cautious as technical weakness combines with valuation concerns. The ETF offers efficient exposure to materials but faces competition from AI-focused sectors. Key risks include sector concentration and cyclical sensitivity, while potential catalysts include infrastructure spending and supply chain diversification efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
